Abstract
Over the last two decades cancer cure rates have not gone up as expected, and the effectiveness of chemotherapy has reached a plateau. This has prompted a search for targeted therapies with higher efficacy and lesser toxicities. Monoclonal antibodies against cancer cells offer targeted therapies with little or no toxicities against normal tissues. In this review we will discuss the concepts behind the development of monoclonal antibodies in cancer and their present status in the clinic. Specifically, we will discuss the clinical use of Rituximab (RituxanÓ), Trastuzumab (HerceptinÓ) and Bevacizumab (AvastinÓ) in various cancers and the key clinical trials that have led to their incorporation in cancer therapeutics.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 943-947 |
| Number of pages | 5 |
| Journal | Indian Journal of Pediatrics |
| Volume | 72 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 2005 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cancer cure
- Chemotherapy
- Monoclonal antibodies
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
Fingerprint
Dive into the research topics of 'Engineered antibodies act as targeted therapies in cancer treatment'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS